Stay up-to-date on the latest news from the CIBMTR.
Recent News
Kite and the CIBMTR® Present Positive Findings From Real-World Use of Yescarta® (Axicabtagene Ciloleucel) in Relapsed or Refractory Large B-Cell Lymphoma
December 9, 2019: Kite, a Gilead Company (Nasdaq: GILD), and the CIBMTR®
(Center for International Blood and Marrow Transplant Research®),
the research collaboration between the National Marrow Donor Program®
(NMDP)/Be The Match® and the Medical College of Wisconsin (MCW),
today announced findings from an ongoing post-marketing study evaluating the
safety and efficacy of Yescarta® (axicabtagene ciloleucel) in adult patients
with relapsed or refractory large B-cell lymphoma. In this analysis, efficacy and safety of
Yescarta were comparable to that observed in the ZUMA-1 trial, despite a larger
proportion of older, more difficult-to-treat patients in the real-world setting. The findings were presented today at the
61st American Society of Hematology (ASH) Annual Meeting &
Exposition, held in Orlando from December 7–10, 2019.
September 11, 2019: Gamida Cell Ltd. (Nasdaq: GMDA), a leading
cellular and immune therapeutics company, and the CIBMTR® (Center
for International Blood and Marrow Transplant Research®) today announced the entry into a research agreement to
collect and analyze health outcomes data in patients with hematologic
malignancies who receive an allogeneic hematopoietic stem cell transplant (HSCT,
or bone marrow transplant) from various donor sources. The CIBMTR
is an organization that collaborates with the global
scientific community to advance hematopoietic cell transplantation (HCT) and
cellular therapy worldwide.
September 14, 2018: A new collaboration focused on tracking long-term outcomes of patients treated with chimeric antigen receptor T-cell (CAR-T) therapies has been established between the CIBMTR® (Center for International Blood and Marrow Transplant Research), and Novartis. Under the terms of the collaboration, CIBMTR will collect long-term safety and efficacy data from patients (pediatrics and adults) treated with Kymriah® (tisagenlecleucel) who agree to participate in the CIBMTR registry for cellular therapy.
May 17, 2018: A new collaboration focused on tracking long-term outcomes of patients treated with chimeric antigen receptor T cell (CAR T) therapies is formed between the CIBMTR® (Center for International Blood and Marrow Transplant Research), and Kite, a Gilead Company. CIBMTR is an organization that collaborates with the global scientific community to advance hematopoietic cell transplantation (HCT) and cellular therapy worldwide. Under the terms of the agreement, CIBMTR will collect and analyze long-term safety and efficacy data for YESCARTA® in a commercial setting.
